Hormones & Genes
Allergens & Inflammation: IgE, Type 2 Pathways, CRP & MCAS Claims
Allergy is not the same as systemic inflammation. Separates IgE from non-IgE disease, maps Type 2 pathways, covers Big 9 foods and LEAP, hs-CRP bands, MCAS triad criteria, and lifestyle adjuncts that do not replace epinephrine.
Allergy pathways (IgE, non-IgE, Type 2) are not the same disease as cardiometabolic sterile inflammation measured by hs-CRP. Sensitization is not clinical allergy. MCAS needs a laboratory-anchored triad. Lifestyle helps markers and control as adjuncts — never as epinephrine substitutes.
Informational editorial content only — not medical advice, not a personal protocol, and not a substitute for clinical care.
Allergen and inflammation content collapses four different biological stories into one wellness word: inflammation. That collapse sells cleanses and mis-sells risk. This guide keeps the classifier honest: IgE Type I allergy, non-IgE delayed hypersensitivity, Type 2 atopic multimorbidity, and sterile systemic acute-phase inflammation used in cardiovascular risk.
How do IgE, non-IgE, and Type 2 pathways differ?
IgE-mediated (Type I) disease: after sensitization, re-exposure cross-links FcεRI on mast cells and basophils within minutes to about two hours. EAACI 2023 guidance centers history plus targeted skin or serum IgE testing and oral food challenge when needed. Non-IgE food allergy is delayed; FPIES classically causes repetitive vomiting one to four hours after culprit foods, often with negative IgE tests. Type 2 inflammation (IL-4/5/13, eosinophils, alarmins such as TSLP) unifies much atopic dermatitis, allergic rhinitis, eosinophilic asthma, and eosinophilic esophagitis without being identical to having allergies. Biologics targeting these nodes validate mechanisms in severe disease under specialty care.
| Dimension | IgE Type I | Non-IgE | Type 2 atopic | Sterile systemic (CV) |
|---|---|---|---|---|
| Onset after exposure | Minutes–~2 h | Hours–days | Chronic/subacute | Days–years tone |
| Key labs | sIgE/SPT ± OFC | Clinical ± challenge | Eos/FeNO ± histology | hs-CRP in context |
| Relation to hs-CRP | Weak as disease meter | Not primary | Occasional overlap | Defining lab axis |
| Lifestyle role | Avoid triggers; AIT specialty | Culprit removal supervised | Barrier/trigger adjuncts | Sleep, diet pattern, air |
What should readers know about foods, airways, and the atopic march?
U.S. Big 9 labeling covers milk, egg, fish, Crustacean shellfish, tree nuts, peanut, wheat, soy, and sesame. LEAP showed early peanut introduction in high-risk infants cut peanut allergy at five years by about eighty-one percent versus avoidance. Aeroallergens split outdoor seasonal pollens from indoor perennial mite, pet, mold, and cockroach sources. United airways: allergic rhinitis and asthma co-travel; assess the nose in asthma and the lungs in rhinitis. The atopic march is probabilistic risk elevation, not destiny. GINA-aligned controllers remain central for persistent asthma.
How should hs-CRP and MCAS claims be graded?
hs-CRP strata for cardiovascular residual risk commonly use less than 1, 1–3, and greater than 3 mg/L after Ridker-class clinical framing. Confounders include BMI, smoking, infection, sleep, and periodontitis. Allergy is not CRP disease. MCAS under Gülen and related criteria reviews requires multi-system recurrent severe symptoms, mediator proof (tryptase greater than 1.2× baseline + 2), and therapy response. Checklist diagnosis is Grade D. IgG food panels for diagnosing IgE allergy are Grade D.
What lifestyle levers help — and what sex patterns matter?
Sleep loss can raise IL-6 and CRP. Mediterranean-style patterns modestly lower sterile markers as Track B; Track A for allergy is indicated allergen elimination with dietitian support when needed. Air quality: PM2.5 and ozone worsen asthma; fix dampness, keep homes smoke-free, ventilate, then filter. Sex switch: childhood asthma is male-predominant; adult asthma often female-predominant. Autoimmunity female skew is a separate axis. Anti-patterns: lactose intolerance as dairy allergy; CRP cleanses for hay fever; HEPA as asthma cure; lifestyle replacing epinephrine.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Evidence grades here follow a simple editorial ladder: Grade A for multi-study human agreement or guideline consensus; Grade B for consistent human signal with residual uncertainty; Grade C for limited or preclinical-only support; Grade D for anecdote, marketing, or mechanism-only claims. Prefer primary agency and trial sources over social media summaries when decisions are personal and medical.
Sources & citations
Frequently asked